Stockscreener 앱 받기
2.10
1.94%
0.04
시간 외 거래:
2.13
0.03
+1.43%
Abcellera Biologics Inc 주식(ABCL)의 최신 뉴스
AbCellera Wins Patent Appeal Against Bruker - TipRanks
AbCellera (ABCL) Wins Patent Validation Case in Federal Circuit - GuruFocus
AbCellera patent upheld in Federal Circuit Court ruling By Investing.com - Investing.com Canada
AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by t - GuruFocus
AbCellera patent upheld in Federal Circuit Court ruling - Investing.com
Abcellera's Microfluidic Cell Culture Patent Affirmed Valid By U.S. Court Of Appeals For Federal Circuit - marketscreener.com
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting - BioSpace
AbCellera plans to advance ABCL635 and ABCL575 into Phase 1 trials in Q3 2025 - MSN
AbCellera Biologics First Quarter 2025 Earnings: Revenues Disappoint - Yahoo Finance
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2025 Earnings Call Transcript - Insider Monkey
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2 - GuruFocus
Stifel Adjusts Price Target for AbCellera (ABCL), Maintains Buy Rating | ABCL Stock News - GuruFocus
AbCellera Biologics Navigates Progress and Challenges in Earnings Call - TipRanks
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates - MSN
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Investments - GuruFocus
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
ABCL635 - AbCellera
AbCellera Biologics Reports Q1 2025 Financial Results - TipRanks
AbCellera (ABCL) Advances Clinical Programs with Strong Financial Position - GuruFocus
Abcellera Biologics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
AbCellera Reports Q1 2025 Business Results - BioSpace
AbCellera (ABCL) Misses Revenue Projections, Advances New Antibody Treatment | ABCL Stock News - GuruFocus
AbCellera Biologics Inc Reports Q1 2025 Earnings: EPS of $(0.15) Misses Estimate, Revenue Falls Short at $4.2 Million - GuruFocus
Abcellera Biologics earnings missed by $0.01, revenue fell short of estimates - Investing.com
2 Reasons to Watch EAT and 1 to Stay Cautious - The Globe and Mail
AbCellera Biologics (ABCL) Q1 Earnings Preview: Analysts Expect Lower Revenue - GuruFocus
AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Report Preview: What To Look For - Yahoo Finance
Abcellera at Bloom Burton: Strategic Shift in Biotech Development By Investing.com - Investing.com UK
Why Lucid Stock Is Sinking Today - The Globe and Mail
Kiwetinohk announces upcoming first quarter 2025 earnings release - The Globe and Mail
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 - BioSpace
AbCellera (ABCL) Unveils Promising Preclinical Results for T-Cel - GuruFocus
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x C - GuruFocus
AbCellera reports promising preclinical TCE cancer therapy data - Investing.com
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 | ABCL Stock News - GuruFocus
Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now? - Insider Monkey
AbCellera Stock: Attractively Priced, But A Catalyst Is Needed (NASDAQ:ABCL) - Seeking Alpha
KeyBanc Increases Price Target for AbCellera (ABCL) Amidst Economic Concerns | ABCL Stock News - GuruFocus
AbCellera (ABCL) to Engage in Upcoming Investor Conferences - GuruFocus
AbCellera (ABCL) to Release Q1 2025 Financial Results on May 8 - GuruFocus
Top Insider Buys Highlight for the Week of Dec. 18 - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June | ABCL Stock News - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June - Business Wire
What to Expect in the Week Ahead: Inflation Data, Bank Earnings, and More Tariff Concerns - The Globe and Mail
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
Abcellera stock hits 52-week low at $2.1 amid market challenges - Investing.com India
Abcellera stock hits 52-week low at $2.1 amid market challenges By Investing.com - Investing.com South Africa
Netflix Poised for Significant Rally as a Safe Haven Stock - The Globe and Mail
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 - Yahoo Finance
3.01%
자본화:
|
볼륨(24시간):